Because of the increased, selective tumor BBB permeability, it has been possible to improve glioma drug uptake for drugs of varying sizes, including anti-HER2 monoclonal antibody and carboplatin, with carboplatin significantly increasing survival in rats bearing RG-2 glioma [57]. This evidence concerns the gene ERBB2 and central nervous system cancer.